Sample characteristics
The basic descriptive statistics for age, gender, WHO classification, WHO grade, surgical methods, chemotherapy, radiotherapy and survival condition were computed and listed in Table 1. There were 575 patients with glioma (320 males and 255 females) and 500 healthy controls (279 males and 221 females) in this case-control study. The mean age of case and control groups was 40.46 years old and 40.53 years old, respectively. The glioma patients consisted of 353 (61.4%) astrocytoma, 36 (6.3%) ependymoma, 36 (6.3%) glioblastoma, 94 (16.3%) oligodendrocytes astrocytoma, 19 (3.3%) oligodendroglioma and 37 (6.4%) other gliomas. There were 369 (64.2%) cases with grade I–II tumors and 206 (35.8%) cases with grade III–IV tumors. 183 (31.8%) patients were treated with STR or NTR; 392 (68.2%) patients were treated with GTR. 364 (63.3%) patients were treated with GK radiotherapy, 155 (27.0%) patients were treated with CRT, and the rest 56 (9.7%) patients did not receive any radiotherapy. 237 (41.2%) patients were treated with chemotherapy (platinum: 118, nimustine: 70, temozolomide: 49, respectively), while 338 (58.8%) patients were not treated. There were 511 (88.9%) deaths, 40 (7.0%) patients survive, and 24 (4.2%) patients are lost to follow-up. No statistically significant differences were found between case and control groups with regarded to age and gender distribution (p > 0.05).
Table 1
Characteristics of patients with glioma and controls
Characteristics | Cases (%) | Controls (%) | P |
Total | 575 | 500 | |
Age, Mean ± SD (year) | 40.46 ± 18.08 | 40.53 ± 13.90 | 0.942 |
Gender | Male | 320 (55.7) | 279 (55.8) | 0.961 |
| Female | 255 (44.3) | 221 (44.2) | |
WHO classification | Astrocytoma | 353 (61.4) | | |
| Ependymoma | 36 (6.3) | | |
| Glioblastoma | 36 (6.3) | | |
| Oligodendrocytes astrocytoma | 94 (16.3) | | |
| Oligodendroglioma | 19 (3.3) | | |
| Others | 37 (6.4) | | |
WHO grade | I–II | 369 (64.2) | | |
| III–IV | 206 (35.8) | | |
Surgical method | STR or NTR | 183 (31.8) | | |
| GTR | 392 (68.2) | | |
Chemotherapy | No | 338 (58.8) | | |
| Platinum | 118 (20.5) | | |
| Nimustine | 70 (12.2) | | |
| Temozolomide | 49 (8.5) | | |
Radiotherapy | No | 56 (9.7) | | |
| CRT | 155 (27.0) | | |
| GK | 364 (63.3) | | |
Survival condition | Survival | 40 (7.0) | | |
| Death | 511 (88.9) | | |
| Lost | 24 (4.2) | | |
SD: standard deviation; WHO: World Health Organization; STR: sub-total resection; NTR: near-total resection; GTR: gross-total resection; CRT: conformal radiotherapy; GK: gamma knife |
P < 0.05 indicates statistical significance. |
PVT1 polymorphisms and glioma risk
This study selected three SNPs in PVT1 which were successfully genotyped (call rate > 95%). The detail information including chromosome id, position, role, allele and potential function predicted, MAF for the SNPs in cases and controls, and HWE of these variants is listed in Table 2. The genotype frequencies of the three SNPs among the controls were in agreement with the HWE (p > 0.05). However, three were no significant differences in the allelic frequency distribution of the three SNPs between the case group and the control group (p > 0.05). No significant association of the three SNPs in PVT1 with glioma risk.
Table 2
Basic information of PVT1 polymorphisms and association with glioma risk
SNP–ID | Chr | Position | Role | Regulome DB Score | Haploreg | Allele A/B | HWE-P | MAF Case | MAF Control | OR (95% CI) | P |
rs4410871 | 8 | 127802783 | Intron | 2b | Promoter histone marks, enhancer histone marks, DNAse, proteins bound, motifs changed, selected eQTL hits | T/C | 0.690 | 0.351 | 0.339 | 1.06 (0.88–1.26) | 0.550 |
rs4733789 | 8 | 127822157 | Intron | 5 | Promoter histone marks, enhancer histone marks, DNAse, motifs changed | T/C | 0.418 | 0.442 | 0.451 | 0.96 (0.81–1.14) | 0.667 |
rs13255292 | 8 | 128064327 | Intron | 4 | Enhancer histone marks, DNAse, proteins bound, motifs changed | T/C | 0.102 | 0.198 | 0.206 | 0.95 (0.77–1.18) | 0.642 |
SNP: single nucleotide polymorphism; Chr: chromosome; HWE: Hardy–Weinberg equilibrium; Regulome DB Score: 2b: TF binding + any motif + DNase Footprint + DNase peak; 4: TF binding + DNase peak; 5: TF binding or DNase peak; eQTL: expression quantitative trait loci; MAF: minor allele frequency; OR: odds ratio; CI: confidence interval. |
P < 0.05 indicates statistical significance. |
To further explore the relationship between PVT1 polymorphisms and glioma risk, we performed a genetic model analysis, as shown in Table 3. The results showed that individuals with the TT genotype of rs13255292 was associated with a decreased risk of glioma compared with those with the CC/CT genotype in the recessive model before and after adjusted with age and gender (OR = 0.53, 95% CI: 0.29–0.99, p = 0.046). However, no any significant association was found between the SNPs (rs4410871 and rs4733789) and risk of glioma.
Table 3
PVT1polymorphisms genotypes distribution and association with glioma risk
SNP-ID | Model | Genotype | Case | Control | OR (95%CI) | P | Adjust OR (95%CI) | P |
rs4410871 | Codominant | CC | 249 (43.3) | 216 (43.2) | 1 | | 1 | |
| | CT | 248 (43.1) | 229 (45.8) | 0.94 (0.73–1.21) | 0.632 | 0.94 (0.73–1.21) | 0.636 |
| | TT | 78 (13.6) | 55 (11.0) | 1.23 (0.83–1.82) | 0.298 | 1.23 (0.83–1.82) | 0.296 |
| Dominant | CC | 249 (43.3) | 216 (43.2) | 1 | | 1 | |
| | CT/TT | 326 (56.7) | 284 (56.8) | 1.00 (0.78–1.27) | 0.973 | 1.00 (0.78–1.27) | 0.976 |
| Recessive | CC/CT | 497 (86.4) | 445 (89.0) | 1 | | 1 | |
| | TT | 78 (13.6) | 55 (11.0) | 1.27 (0.88–1.84) | 0.203 | 1.27 (0.88–1.84) | 0.202 |
| Additive | | | | 1.06 (0.88–1.26) | 0.553 | 1.06 (0.88–1.26) | 0.549 |
rs4733789 | Codominant | CC | 179 (31.1) | 146 (29.2) | 1 | | 1 | |
| | CT | 284 (49.4) | 257 (51.4) | 0.90 (0.68–1.19) | 0.461 | 0.90 (0.68–1.19) | 0.46 |
| | TT | 112 (19.5) | 97 (19.4) | 0.94 (0.66–1.34) | 0.736 | 0.94 (0.66–1.34) | 0.734 |
| Dominant | CC | 179 (31.1) | 146 (29.2) | 1 | | 1 | |
| | CT/TT | 396 (68.9) | 354 (70.8) | 0.91 (0.70–1.19) | 0.492 | 0.91 (0.70–1.19) | 0.49 |
| Recessive | CC/CT | 463 (80.5) | 403 (80.6) | 1 | | 1 | |
| | TT | 112 (19.5) | 97 (19.4) | 1.01 (0.74–1.36) | 0.974 | 1.01 (0.74–1.36) | 0.976 |
| Additive | | | | 0.96 (0.81–1.14) | 0.664 | 0.96 (0.81–1.14) | 0.661 |
rs13255292 | Codominant | CC | 364 (63.4) | 320 (64.3) | 1 | | 1 | |
| | CT | 193 (33.6) | 151 (30.3) | 1.12 (0.87–1.46) | 0.381 | 1.13 (0.87–1.46) | 0.378 |
| | TT | 17 (3.0) | 27 (5.4) | 0.55 (0.30–1.03) | 0.064 | 0.55 (0.30–1.04) | 0.064 |
| Dominant | CC | 364 (63.4) | 320 (64.3) | 1 | | 1 | |
| | CT/TT | 210 (36.6) | 178 (35.7) | 1.04 (0.81–1.33) | 0.775 | 1.04 (0.81–1.33) | 0.773 |
| Recessive | CC/CT | 557 (97.0) | 471 (94.6) | 1 | | 1 | |
| | TT | 17 (3.0) | 27 (5.4) | 0.53 (0.29–0.99) | 0.046 | 0.53 (0.29–0.99) | 0.046 |
| Additive | | | | 0.95 (0.77–1.18) | 0.642 | 0.95 (0.77–1.18) | 0.643 |
SNP: single nucleotide polymorphism; OR: odds ratio; CI: confidence interval. |
Adjust OR (95%CI) were calculated by logistic regression analysis with adjustments for age and gender. |
p < 0.05 indicates statistical significance. |
In order to reduce the impact of age and gender on the results of statistical analysis, we conducted stratification analysis (Table 4). Our results found that individuals with the TT genotype of rs4410871 was associated with an increased risk of glioma compared with those with the CC genotype in age ≤ 40 years old (OR = 2.05, 95% CI: 1.12–3.75, p = 0.020). Meanwhile, rs4410871 was found to be associated with an increased risk of glioma in the recessive model in age ≤ 40 years old (TT vs. CC/CT: OR = 2.33, 95% CI: 1.31–4.15, p = 0.004).
Table 4
Association of PVT1 polymorphisms with glioma risk stratified by age and gender
SNP_ID | Model | Genotype | Age > 40 | Age ≤ 40 |
Case (%) | Control (%) | OR (95% CI) | P | Case (%) | Control (%) | OR (95% CI) | P |
rs4410871 | Codominant | CC | 120 (40.5) | 100 (42.6) | 1 | | 129 (46.2) | 116 (43.8) | 1 | |
| | CT | 139 (47) | 100 (42.6) | 1.17 (0.81–1.70) | 0.410 | 109 (39.1) | 129 (48.7) | 0.77 (0.53–1.11) | 0.163 |
| | TT | 37 (12.5) | 35 (14.9) | 0.92 (0.54–1.57) | 0.754 | 41 (14.7) | 20 (7.5) | 2.05 (1.12–3.75) | 0.020 |
| Dominant | CC | 120 (40.5) | 100 (42.6) | 1 | | 129 (46.2) | 116 (43.8) | 1 | |
| | CT/TT | 176 (59.5) | 135 (57.4) | 1.11 (0.78–1.57) | 0.575 | 150 (53.8) | 149 (56.2) | 0.94 (0.66–1.32) | 0.705 |
| Recessive | CC/CT | 259 (87.5) | 200 (85.1) | 1 | | 238 (85.3) | 245 (92.5) | 1 | |
| | TT | 37 (12.5) | 35 (14.9) | 0.85 (0.51–1.40) | 0.511 | 41 (14.7) | 20 (7.5) | 2.33 (1.31–4.15) | 0.004 |
| Additive | | | | 1.01 (0.79–1.30) | 0.941 | | | 1.16 (0.89–1.50) | 0.270 |
rs4733789 | Codominant | CC | 101 (34.1) | 65 (27.7) | 1 | | 78 (28) | 81 (30.6) | 1 | |
| | CT | 138 (46.6) | 124 (52.8) | 0.72 (0.48–1.07) | 0.100 | 146 (52.3) | 133 (50.2) | 1.12 (0.75–1.66) | 0.594 |
| | TT | 57 (19.3) | 46 (19.6) | 0.80 (0.48–1.32) | 0.378 | 55 (19.7) | 51 (19.2) | 1.10 (0.66–1.82) | 0.723 |
| Dominant | CC | 101 (34.1) | 65 (27.7) | 1 | | 78 (28) | 81 (30.6) | 1 | |
| | CT/TT | 195 (65.9) | 170 (72.3) | 0.74 (0.51–1.08) | 0.114 | 201 (72) | 184 (69.4) | 1.11 (0.76–1.62) | 0.591 |
| Recessive | CC/CT | 239 (80.7) | 189 (80.4) | 1 | | 224 (80.3) | 214 (80.8) | 1 | |
| | TT | 57 (19.3) | 46 (19.6) | 0.98 (0.63–1.51) | 0.929 | 55 (19.7) | 51 (19.2) | 1.02 (0.66–1.58) | 0.922 |
| Additive | | | | 0.87 (0.68–1.11) | 0.274 | | | 1.05 (0.82–1.35) | 0.681 |
rs13255292 | Codominant | CC | 187 (63.4) | 150 (63.8) | 1 | | 177 (63.4) | 170 (64.6) | 1 | |
| | CT | 96 (32.5) | 73 (31.1) | 1.03 (0.71–1.50) | 0.881 | 97 (34.8) | 78 (29.7) | 1.30 (0.89–1.90) | 0.168 |
| | TT | 12 (4.1) | 12 (5.1) | 0.87 (0.38-2.00) | 0.737 | 5 (1.8) | 15 (5.7) | 0.39 (0.14–1.11) | 0.076 |
| Dominant | CC | 187 (63.4) | 150 (63.8) | 1 | | 177 (63.4) | 170 (64.6) | 1 | |
| | CT/TT | 108 (36.6) | 85 (36.2) | 1.01 (0.70–1.44) | 0.971 | 102 (36.6) | 93 (35.4) | 1.16 (0.81–1.67) | 0.418 |
| Recessive | CC/CT | 283 (95.9) | 223 (94.9) | 1 | | 274 (98.2) | 248 (94.3) | 1 | |
| | TT | 12 (4.1) | 12 (5.1) | 0.86 (0.38–1.96) | 0.718 | 5 (1.8) | 15 (5.7) | 0.35 (0.12-1.00) | 0.050 |
| Additive | | | | 0.99 (0.73–1.33) | 0.921 | | | 1.00 (0.73–1.36) | 0.996 |
| | | Male | Female |
rs4410871 | Codominant | CC | 135 (42.19) | 111 (39.78) | 1 | | 114 (44.71) | 105 (47.51) | 1 | |
| | CT | 142 (44.38) | 130 (46.59) | 0.90 (0.64–1.27) | 0.547 | 106 (41.57) | 99 (44.8) | 0.99 (0.67–1.44) | 0.943 |
| | TT | 43 (13.44) | 38 (13.62) | 0.93 (0.56–1.54) | 0.783 | 35 (13.73) | 17 (7.69) | 1.90 (1.00-3.59) | 0.049 |
| Dominant | CC | 135 (42.19) | 111 (39.78) | 1 | | 114 (44.71) | 105 (47.51) | 1 | |
| | CT/TT | 185 (57.81) | 168 (60.22) | 0.91 (0.65–1.26) | 0.556 | 141 (55.29) | 116 (52.49) | 1.12 (0.78–1.61) | 0.540 |
| Recessive | CC/CT | 277 (86.56) | 241 (86.38) | 1 | | 220 (86.27) | 204 (92.31) | 1 | |
| | TT | 43 (13.44) | 38 (13.62) | 0.99 (0.62–1.58) | 0.952 | 35 (13.73) | 17 (7.69) | 1.91 (1.04–3.51) | 0.038 |
| Additive | | | | 0.95 (0.75–1.20) | 0.651 | | | 1.22 (0.93–1.60) | 0.151 |
rs4733789 | Codominant | CC | 96 (30) | 86 (30.82) | 1 | | 83 (32.55) | 60 (27.15) | 1 | |
| | CT | 169 (52.81) | 144 (51.61) | 1.05 (0.73–1.52) | 0.790 | 115 (45.1) | 113 (51.13) | 0.74 (0.48–1.12) | 0.154 |
| | TT | 55 (17.19) | 49 (17.56) | 1.01 (0.62–1.63) | 0.982 | 57 (22.35) | 48 (21.72) | 0.86 (0.52–1.43) | 0.555 |
| Dominant | CC | 96 (30) | 86 (30.82) | 1 | | 83 (32.55) | 60 (27.15) | 1 | |
| | CT/TT | 224 (70) | 193 (69.18) | 1.04 (0.73–1.47) | 0.828 | 172 (67.45) | 161 (72.85) | 0.77 (0.52–1.15) | 0.201 |
| Recessive | CC/CT | 265 (82.81) | 230 (82.44) | 1 | | 198 (77.65) | 173 (78.28) | 1 | |
| | TT | 55 (17.19) | 49 (17.56) | 0.97 (0.64–1.49) | 0.904 | 57 (22.35) | 48 (21.72) | 1.04 (0.67–1.60) | 0.867 |
| Additive | | | | 1.01 (0.80–1.28) | 0.936 | | | 0.91 (0.71–1.17) | 0.470 |
rs13255292 | Codominant | CC | 210 (65.83) | 184 (66.19) | 1 | | 154 (60.39) | 136 (61.82) | 1 | |
| | CT | 100 (31.35) | 76 (27.34) | 1.16 (0.81–1.65) | 0.431 | 93 (36.47) | 75 (34.09) | 1.10 (0.75–1.60) | 0.641 |
| | TT | 9 (2.82) | 18 (6.47) | 0.44 (0.19-1.00) | 0.051 | 8 (3.14) | 9 (4.09) | 0.79 (0.29–2.09) | 0.628 |
| Dominant | CC | 210 (65.83) | 184 (66.19) | 1 | | 154 (60.39) | 136 (61.82) | 1 | |
| | CT/TT | 109 (34.17) | 94 (33.81) | 1.02 (0.72–1.43) | 0.917 | 101 (39.61) | 84 (38.18) | 1.06 (0.73–1.54) | 0.751 |
| Recessive | CC/CT | 310 (97.18) | 260 (93.53) | 1 | | 247 (96.86) | 211 (95.91) | 1 | |
| | TT | 9 (2.82) | 18 (6.47) | 0.42 (0.19–0.95) | 0.037 | 8 (3.14) | 9 (4.09) | 0.76 (0.29-2.00) | 0.578 |
| Additive | | | | 0.91 (0.68–1.20) | 0.489 | | | 1.02 (0.74–1.40) | 0.928 |
SNP: single nucleotide polymorphism; OR: odds ratio; CI: confidence interval. |
OR (95% CI) were calculated by logistic regression analysis with adjustments for age and gender. |
p < 0.05 indicates statistical significance. |
Gender stratification analysis results showed that rs4410871 was also associated with an increased risk of glioma in female after adjusted with age (TT vs. CC: OR = 1.90, 95% CI: 1.00–3.59, p = 0.049; TT vs. CC/CT: OR = 1.91, 95% CI: 1.04–3.51, p = 0.038). Moreover, rs13255292 was found to be associated with a reduced risk of glioma in the recessive model in male after adjusted with age (TT vs. CC/CT: OR = 0.42, 95% CI: 0.19–0.95, p = 0.037) (Table 4).
Clinical factors and prognosis of glioma patients
We also investigated the impact clinical factors on the OS and PFS of glioma patients (Table 5). The univariate and Cox regression analysis results that the glioma patients with gross-total resection (GTR) was also associated with a reduced risk of death on OS (log-rank p < 0.001, HR = 0.63, 95% CI: 0.52–0.76, p < 0.001) and PFS (log-rank p < 0.001, HR = 0.59, 95% CI: 0.49–0.71, p < 0.001), compared with the glioma patients with near-total resection (NTR) or sub-total resection (STR). In addition, we also found that the glioma patients with the chemotherapy treatment had a longer OS (log-rank p < 0.001) and PFS (log-rank p = 0.012), and had a better prognosis of glioma patients (OS: HR = 0.67, 95% CI: 0.56–0.81, p < 0.001; PFS: HR = 0.81, 95% CI: 0.67–0.97, p = 0.025), compared with the no chemotherapy treatment. The Kaplan Meier survival curve described the survival rates of glioma patients with extent of resection (Fig. 1) and chemotherapy (Fig. 2) treatments, respectively. However, no significant associations were found between the age, gender, WHO grade, radiotherapy and the prognosis of glioma patients as measured by OS and PFS.
Table 5
Univariate analysis of the impact of clinical factors and PVT1 polymorphisms on glioma patient OS and PFS
Variable | Classification | No. of patients/events | OS | No. of patients/events | PFS |
1 year ST % | MST (month) | Log-rank p | HR (95%CI) | p | 1 year ST % | MST (month) | Log-rank p | HR (95%CI) | p |
Gender | Male | 321/284 | 32.6 | 11 | | 1 | | 319/282 | 20.3 | 8 | | 1 | |
| Female | 257/230 | 30.7 | 11 | 0.352 | 1.08 (0.91–1.28) | 0.394 | 254/228 | 15.3 | 8 | 0.241 | 1.10 (0.92–1.31) | 0.293 |
Age(years) | < 40 | 258/221 | 35.1 | 12 | | 1 | | 254/218 | 20.2 | 8 | | 1 | |
| ≥ 40 | 320/293 | 29.1 | 11 | 0.061 | 1.17 (0.98–1.39) | 0.086 | 319/292 | 16.4 | 8 | 0.121 | 1.13 (0.95–1.35) | 0.164 |
WHO grade | I | 371/324 | 32.8 | 12 | | 1 | | 369/322 | 19.1 | 8 | | 1 | |
| Ⅱ | 207/190 | 30.0 | 10 | 0.094 | 1.15 (0.96–1.38) | 0.125 | 204/188 | 16.3 | 8 | 0.122 | 1.14 (0.95–1.36) | 0.166 |
Extent of resection | STR or NTR | 184/181 | 19.6 | 12 | | 1 | | 181/178 | 1.70 | 8 | | 1 | |
| GTR | 394/333 | 37.5 | 11 | < 0.001 | 0.63 (0.52–0.76) | < 0.001 | 392/332 | 25.8 | 8 | < 0.001 | 0.59 (0.49–0.71) | < 0.001 |
Radiotherapy | No | 57/46 | 43.9 | 12 | | 1 | | 54/43 | 20.4 | 10 | | 1 | |
| CRT | 156/128 | 24.0 | 10 | | | | 155/127 | 21.5 | 8 | | | |
| Gamma knife | 365/340 | 33.2 | 11 | 0.523 | 1.07 (0.94–1.22) | 0.314 | 364/340 | 16.5 | 8 | 0.096 | 1.08 (0.95–1.24) | 0.231 |
Chemotherapy | No | 341/319 | 27.0 | 9 | | 1 | | 340/318 | 16.8 | 7 | | 1 | |
| Yes | 237/195 | 38.7 | 12 | < 0.001 | 0.67 (0.56–0.81) | < 0.001 | 233/192 | 20.1 | 8 | 0.012 | 0.81 (0.68–0.97) | 0.025 |
rs4410871 | CC | 250/221 | 34.7 | 11 | | 1 | | 248/219 | 18.7 | 8 | | 1 | |
| CT | 250/225 | 30.8 | 11 | | 0.98 (0.75–1.29) | 0.905 | 247/223 | 17.8 | 8 | | 0.98 (0.75–1.28) | 0.872 |
| TT | 78/68 | 25.6 | 11 | 0.809 | 1.05 (0.87–1.26) | 0.611 | 78/68 | 17.0 | 8 | 0.899 | 1.03 (0.85–1.24) | 0.762 |
rs4733789 | CC | 181/163 | 28.7 | 11 | | 1 | | 180/162 | 17.4 | 8 | | 1 | |
| CT | 285/249 | 33.9 | 11 | | 0.99 (0.78–1.27) | 0.953 | 282/247 | 20.4 | 8 | | 0.97 (0.76–1.25) | 0.818 |
| TT | 112/102 | 31.3 | 12 | 0.763 | 0.94 (0.77–1.15) | 0.537 | 111/101 | 13.5 | 8 | 0.588 | 0.91 (0.75–1.11) | 0.37 |
rs13255292 | CC | 365/325 | 30.4 | 11 | | 1 | | 361/321 | 17.7 | 8 | | 1 | |
| CT | 195/171 | 34.1 | 12 | | 1.16 (0.71–1.89) | 0.555 | 194/171 | 18.4 | 8 | | 1.13 (0.69–1.84) | 0.632 |
| TT | 17/17 | 29.4 | 10 | 0.333 | 0.90 (0.75–1.08) | 0.257 | 17/17 | 17.6 | 8 | 0.407 | 0.91 (0.75–1.09) | 0.303 |
WHO: World Health Organization; GTR: gross-total resection; NTR: near-total resection; STR: sub-total resection; OS: overall survival; PFS: progression free survival; ST: survival rate; MST: median survival time |
HR: hazard ratio; 95% CI: 95% confidence interval |
P < 0.05 indicates statistical significance. |
PVT1 polymorphisms and prognosis of glioma patients
We used the log-rank tests, Cox regression analysis (univariate and multivariate) and Kaplan Meier analysis to evaluate the effect of the four PVT1 polymorphisms on the glioma patients with OS and PFS (Table 5 and Table 6). However, there were no significant associations were found between the polymorphisms of PVT1 and the prognosis of glioma patients.
Table 6
Univariate analysis of the association between and glioma patient OS and PFS
SNP-ID | Genotype | OS | | PFS | |
HR (95%CI) | p | HR (95%CI) | p |
rs4410871 | CC | 1 | | 1 | |
| CT | 0.97 (0.73–1.27) | 0.800 | 0.94 (0.71–1.23) | 0.642 |
| TT | 1.00 (0.83–1.21) | 0.973 | 0.99 (0.82–1.19) | 0.882 |
rs4733789 | CC | 1 | | 1 | |
| CT | 1.11 (0.86–1.42) | 0.435 | 1.06 (0.83–1.36) | 0.639 |
| TT | 1.08 (0.89–1.32) | 0.444 | 1.05 (0.86–1.29) | 0.612 |
rs13255292 | CC | 1 | | 1 | |
| CT | 1.01 (0.62–1.65) | 0.959 | 0.96 (0.59–1.56) | 0.862 |
| TT | 0.90 (0.75–1.09) | 0.277 | 0.86 (0.71–1.03) | 0.099 |
SNP: single nucleotide polymorphism; OS: overall survival; PFS: progression free survival; HR: hazard ratio; 95% CI: 95% confidence interval |
P < 0.05 indicates statistical significance. |